“Deucravacitinib in Plaque Psoriasis: 3-Year Safety and Efficacy Results from the Phase 3 POETYK PSO-1 and PSO-2 Trials”. SKIN The Journal of Cutaneous Medicine, vol. 8, no. 2, Mar. 2024, p. s366, https://doi.org/10.25251/skin.8.supp.366.